Actively Recruiting
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Led by University of Edinburgh · Updated on 2025-08-19
290
Participants Needed
1
Research Sites
243 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot of these conditions are still not fully understood and treatment options are limited. We here aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of heart muscle scarring. This radioactive dye is being used in humans particularly in identifying and monitoring cancers and has shown promise in identifying scarring in the heart as well. This will help us not only understand the underlying disease process and risk stratify these patients but also potentially help us develop new targeted therapies that can affect heart muscle scarring. Participants will undergo a baseline MRI scan using this new dye and a plain MRI scan will repeated 12-18 months after to see if there are any changes in the process.
CONDITIONS
Official Title
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged between 30 and 90 years
- Provide informed consent before any study procedures
- For heart failure with preserved ejection fraction: have symptoms like breathlessness, reduced exercise tolerance, or fatigue; signs such as elevated jugular venous pressure, pulmonary crackles, or swelling; and echocardiographic features including preserved left ventricular systolic function (>50%) and reduced diastolic function
- For hypertrophic cardiomyopathy: diagnosed with left ventricular wall thickness >15mm without loading conditions, or >13mm with supporting features like family history or ECG changes
- For hypertensive heart disease: diagnosed with essential hypertension for at least 1 year and evidence of left ventricular hypertrophy on echocardiography
- For arrhythmogenic cardiomyopathy: diagnosed based on International Task Force 2010 criteria
- For myocarditis: diagnosed in the past month with chest pain, signs of pericarditis, elevated troponin, unobstructed coronary arteries, or cardiac MRI evidence
- For takotsubo cardiomyopathy: diagnosed in the past month according to European Society of Cardiology guidelines 2018
- For cardiac sarcoidosis: diagnosed for at least 1 year based on expert opinion with histological diagnosis and one or more cardiac manifestations responsive to treatment or specific imaging findings
You will not qualify if you...
- Unable or unwilling to give informed consent
- History of claustrophobia or unable to lie flat for PET/MR or PET/CT scans
- Impaired kidney function with eGFR less than 30 mL/min/1.73 m2
- Pregnant or breastfeeding women
- Allergy to iodine or gadolinium contrast agents
- Contraindication to CT scanning
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Edinburgh
Edinburgh, Scotland, United Kingdom, EH16 5RR
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here